Best practice: solid risk management plan
|Sini Eskola has been director of regulatory affairs at the European Federation of Pharmaceutical Industries and Associations (EFPIA) sinceFebruary 2014. Prior to joining EFPIA, she worked at AstraZeneca’s R&D|Risk management is necessary in clinical trials to protect patients.|A good RMP should maximise patient safety without stymieing drug development.